| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 339 | 2021 |
| Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... New England Journal of Medicine 383 (26), 2526-2537, 2020 | 324 | 2020 |
| Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Heuser, Y Ofran, N Boissel, SB Mauri, C Craddock, J Janssen, ... Annals of Oncology 31 (6), 697-712, 2020 | 228 | 2020 |
| Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death JK Altman, A Rademaker, E Cull, BB Weitner, Y Ofran, TL Rosenblat, ... Leukemia research 37 (9), 1004-1009, 2013 | 119 | 2013 |
| The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in … AH Wei, H Döhner, C Pocock, P Montesinos, B Afanasyev, H Dombret, ... Blood 134, LBA-3, 2019 | 117 | 2019 |
| Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: a prospective controlled trial I Oren, H Sprecher, R Finkelstein, S Hadad, A Neuberger, K Hussein, ... American journal of infection control 41 (12), 1167-1172, 2013 | 102 | 2013 |
| Patterns of information-seeking for cancer on the internet: an analysis of real world data Y Ofran, O Paltiel, D Pelleg, JM Rowe, E Yom-Tov Public Library of Science 7 (9), e45921, 2012 | 82 | 2012 |
| Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter … P Montesinos, GJ Roboz, CE Bulabois, M Subklewe, U Platzbecker, ... Leukemia 35 (1), 62-74, 2021 | 76 | 2021 |
| Predicting infections in high‐risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study D Merkel, K Filanovsky, A Gafter‐Gvili, L Vidal, A Aviv, ME Gatt, ... American journal of hematology 88 (2), 130-134, 2013 | 72 | 2013 |
| The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy E Elinav, I Ben-Dov, E Hai-Am, Z Ackerman, Y Ofran Journal of hepatology 42 (1), 82-86, 2005 | 65 | 2005 |
| Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations RB Walter, Y Ofran, A Wierzbowska, F Ravandi, CS Hourigan, LL Ngai, ... Leukemia 35 (6), 1529-1538, 2021 | 64 | 2021 |
| Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia Y Ofran, S Ringelstein-Harlev, I Slouzkey, T Zuckerman, D Yehudai-Ofir, ... Leukemia 34 (1), 293-295, 2020 | 62 | 2020 |
| Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study N Andria, O Henig, O Kotler, A Domchenko, I Oren, T Zuckerman, Y Ofran, ... Journal of Antimicrobial Chemotherapy 70 (11), 3146-3153, 2015 | 62 | 2015 |
| Fatal voluntary salt intake resulting in the highest ever documented sodium plasma level in adults (255 mmol L−1): a disorder linked to female gender and … Y Ofran, D Lavi, D Opher, TA Weiss, E Elinav Journal of internal medicine 256 (6), 525-528, 2004 | 59 | 2004 |
| Genetic profiling in acute myeloid leukaemia─ where are we and what is its role in patient management Y Ofran, JM Rowe British journal of haematology 160 (3), 303-320, 2013 | 58 | 2013 |
| Treatment for relapsed acute myeloid leukemia: what is new? Y Ofran, JM Rowe Current opinion in hematology 19 (2), 89-94, 2012 | 54 | 2012 |
| Near‐fatal amitraz intoxication: The overlooked pesticide E Elinav, Y Shapira, Y Ofran, T Hassin, IZ Ben‐Dov Basic & clinical pharmacology & toxicology 97 (3), 185-187, 2005 | 52 | 2005 |
| Granulocyte transfusions for neutropenic patients with life‐threatening infections: a single centre experience in 47 patients, who received 348 granulocyte transfusions Y Ofran, I Avivi, A Oliven, I Oren, T Zuckerman, L Bonstein, JM Rowe, ... Vox sanguinis 93 (4), 363-369, 2007 | 51 | 2007 |
| BCR-ABL (Ph)-like acute leukemia—pathogenesis, diagnosis and therapeutic options Y Ofran, S Izraeli Blood reviews 31 (2), 11-16, 2017 | 46 | 2017 |
| How I treat acute myeloid leukemia presenting with preexisting comorbidities Y Ofran, MS Tallman, JM Rowe Blood, The Journal of the American Society of Hematology 128 (4), 488-496, 2016 | 45 | 2016 |
